• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞-胆管细胞癌的临床特征、组织学及组织发生

Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma.

作者信息

Gera Shweta, Ettel Mark, Acosta-Gonzalez Gabriel, Xu Ruliang

机构信息

Shweta Gera, Department of Pathology, Montefiore Medical Center, Bronx, NY 10467, United States.

出版信息

World J Hepatol. 2017 Feb 28;9(6):300-309. doi: 10.4254/wjh.v9.i6.300.

DOI:10.4254/wjh.v9.i6.300
PMID:28293379
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5332419/
Abstract

Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities.

摘要

肝细胞胆管癌(CHC)是一种预后较差的罕见肿瘤,在所有原发性肝肿瘤中的发病率为1.0%-4.7%。该实体即将更名为肝内胆管癌。已知的肝细胞癌(HCC)危险因素也与CHC有关,包括病毒性肝炎和肝硬化。术前诊断这种肿瘤很困难。肿瘤内主要的组织学成分在很大程度上决定了主要的影像学特征,这使得鉴别诊断变得困难。HCC和胆管癌的异质性和重叠性影像学特征应引起对CHC的怀疑,建议在进行治疗前进行多次(从肿瘤不同区域获取)核心活检。血清肿瘤标志物CA19-9和甲胎蛋白有助于诊断,但在切除前仍是一项具有挑战性的诊断。有足够的数据支持双潜能肝祖细胞作为CHC的起源细胞。目前世界卫生组织的分类根据组织形态学特征将CHC分为两种主要类型:经典型和具有干细胞特征的CHC。肝移植是可用的治疗方式之一,其他治疗选择包括经动脉化疗栓塞、射频消融和经皮乙醇注射。我们发表一篇关于CHC的综述文章,重点介绍其危险因素、起源、组织学分类和治疗方式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd97/5332419/e901c2bc7222/WJH-9-300-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd97/5332419/8db4d599d0c5/WJH-9-300-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd97/5332419/d8baddd30f5e/WJH-9-300-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd97/5332419/688314423cec/WJH-9-300-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd97/5332419/e901c2bc7222/WJH-9-300-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd97/5332419/8db4d599d0c5/WJH-9-300-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd97/5332419/d8baddd30f5e/WJH-9-300-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd97/5332419/688314423cec/WJH-9-300-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd97/5332419/e901c2bc7222/WJH-9-300-g004.jpg

相似文献

1
Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma.肝细胞-胆管细胞癌的临床特征、组织学及组织发生
World J Hepatol. 2017 Feb 28;9(6):300-309. doi: 10.4254/wjh.v9.i6.300.
2
Combined hepatocellular-cholangiocarcinoma: An update on epidemiology, classification, diagnosis and management.肝细胞-胆管细胞癌联合型:流行病学、分类、诊断及管理的最新进展
Hepatobiliary Pancreat Dis Int. 2020 Dec;19(6):515-523. doi: 10.1016/j.hbpd.2020.07.004. Epub 2020 Jul 24.
3
Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.源自同一克隆的肝细胞癌和胆管癌合并癌:一项基于病理分子证据的研究。
Chin J Cancer. 2016 Aug 24;35(1):82. doi: 10.1186/s40880-016-0146-7.
4
Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.与其他肝癌相比,肝细胞癌-胆管细胞癌混合癌的临床和病理特征。
J Gastroenterol Hepatol. 2019 Jun;34(6):1074-1080. doi: 10.1111/jgh.14547. Epub 2018 Dec 16.
5
Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.肝细胞癌合并胆管癌的突变图谱及其临床病理意义。
Histopathology. 2017 Feb;70(3):423-434. doi: 10.1111/his.13084. Epub 2016 Nov 15.
6
Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.超声造影和肿瘤标志物在鉴别肝内胆管癌与肝细胞癌及胆管癌中的潜在诊断效能
J Med Ultrason (2001). 2018 Apr;45(2):231-241. doi: 10.1007/s10396-017-0834-1. Epub 2017 Oct 20.
7
Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.根据最新的世界卫生组织分类,对肝细胞癌-胆管细胞癌联合癌进行临床病理分析。
Am J Surg Pathol. 2013 Apr;37(4):496-505. doi: 10.1097/PAS.0b013e31827332b0.
8
α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.甲胎蛋白阳性胃癌和肝细胞癌-胆管细胞癌混合型在形态学上相似,但在 SALL4 表达方面具有不同的组织发生。
Hum Pathol. 2012 Nov;43(11):1955-63. doi: 10.1016/j.humpath.2011.11.022. Epub 2012 Apr 17.
9
Recent Topics Concerning Combined Hepatocellular Cholangiocarcinoma.联合肝细胞胆管细胞癌相关的最新研究课题。
Kurume Med J. 2020 Jul 1;66(1):29-36. doi: 10.2739/kurumemedj.MS661014. Epub 2020 May 1.
10
Contrast-enhanced ultrasound imaging features and clinical characteristics of combined hepatocellular cholangiocarcinoma: comparison with hepatocellular carcinoma and cholangiocarcinoma.肝细胞胆管癌的超声造影成像特征及临床特点:与肝细胞癌和胆管癌的比较
Ultrasonography. 2020 Oct;39(4):356-366. doi: 10.14366/usg.19093. Epub 2020 Mar 13.

引用本文的文献

1
Radiologic and Pathologic Insights in Combined Hepatocellular-Cholangiocarcinoma: A Report of Three Cases.肝细胞-胆管细胞癌的影像学与病理学见解:三例报告
Reports (MDPI). 2025 Aug 8;8(3):142. doi: 10.3390/reports8030142.
2
Combined hepatocellular carcinoma-cholangiocarcinoma with sarcomatoid features: new insights into a rare and aggressive tumor.具有肉瘤样特征的肝细胞癌-胆管癌合并症:对一种罕见侵袭性肿瘤的新见解
J Gastrointest Oncol. 2024 Dec 31;15(6):2748-2750. doi: 10.21037/jgo-24-752. Epub 2024 Dec 11.
3
An Integrated Framework to Identify Prognostic Biomarkers and Novel Therapeutic Targets in Hepatocellular Carcinoma-Based Disabilities.

本文引用的文献

1
The expression of arginase-1, keratin (K) 8 and K18 in combined hepatocellular-cholangiocarcinoma, subtypes with stem-cell features, intermediate-cell type.精氨酸酶-1、角蛋白(K)8和K18在具有干细胞特征的中间细胞型肝细胞-胆管癌合并症中的表达。
J Clin Pathol. 2016 Oct;69(10):846-51. doi: 10.1136/jclinpath-2015-203491. Epub 2016 Mar 11.
2
Current update on combined hepatocellular-cholangiocarcinoma.肝细胞胆管癌联合诊疗的最新进展
Eur J Radiol Open. 2014 Sep 6;1:40-8. doi: 10.1016/j.ejro.2014.07.001. eCollection 2014.
3
Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database.
一种基于肝细胞癌相关残疾来识别预后生物标志物和新型治疗靶点的综合框架。
Biology (Basel). 2024 Nov 24;13(12):966. doi: 10.3390/biology13120966.
4
Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?对于胆管癌成分少于10%的肝细胞癌-胆管癌合并症与肝细胞癌,是否有必要进行区分?
Hepatol Int. 2024 Sep 19. doi: 10.1007/s12072-024-10730-1.
5
Sarcomatoid change in combined hepatocellular carcinoma and cholangiocarcinoma as a poor prognostic factor.肝细胞癌合并胆管癌中的肉瘤样改变作为一个预后不良因素。
J Gastrointest Oncol. 2024 Aug 31;15(4):1796-1804. doi: 10.21037/jgo-24-313. Epub 2024 Aug 22.
6
MRI features of combined hepatocellular-cholangiocarcinoma.肝细胞-胆管细胞癌的磁共振成像特征
Abdom Radiol (NY). 2025 Jan;50(1):169-184. doi: 10.1007/s00261-024-04476-5. Epub 2024 Jul 20.
7
Current advances and future directions in combined hepatocellular and cholangiocarcinoma.肝细胞癌合并胆管癌的当前进展与未来方向
Gastroenterol Rep (Oxf). 2024 Apr 15;12:goae031. doi: 10.1093/gastro/goae031. eCollection 2024.
8
How to differentiate between combined hepatocellular carcinoma-cholangiocarcinoma and intrahepatic cholangiocarcinoma with rim arterial phase hyperenhancement?如何区分具有边缘动脉期增强的肝细胞癌-胆管细胞癌和肝内胆管细胞癌?
Abdom Radiol (NY). 2024 Sep;49(9):3015-3023. doi: 10.1007/s00261-024-04194-y. Epub 2024 Mar 1.
9
Update on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma.肝细胞胆管癌联合诊断与治疗的最新进展
J Clin Transl Hepatol. 2024 Feb 28;12(2):210-217. doi: 10.14218/JCTH.2023.00189. Epub 2023 Nov 15.
10
Incidental combined hepatocellular-cholangiocarcinoma in liver transplant patients: Does it have a worse prognosis?肝移植患者中偶然发现的肝细胞-胆管细胞癌合并症:其预后是否更差?
Hepatol Forum. 2023 Sep 20;4(3):97-102. doi: 10.14744/hf.2022.2022.0037. eCollection 2023.
肝细胞癌合并胆管癌患者肝移植的长期预后:美国器官共享联合网络数据库分析
HPB (Oxford). 2016 Jan;18(1):29-34. doi: 10.1016/j.hpb.2015.10.001. Epub 2016 Jan 7.
4
Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.肝细胞癌-胆管癌、肝细胞癌及肝内胆管癌联合切除术后的结果
J Gastrointest Surg. 2016 Feb;20(2):411-20. doi: 10.1007/s11605-015-3045-3. Epub 2015 Dec 1.
5
Spalt-like transcription factor 4 immunopositivity is associated with epithelial cell adhesion molecule expression in combined hepatocellular carcinoma and cholangiocarcinoma.Spalt样转录因子4免疫阳性与肝细胞癌合并胆管癌中上皮细胞黏附分子表达相关。
Histopathology. 2016 Apr;68(5):693-701. doi: 10.1111/his.12806. Epub 2015 Oct 16.
6
Clinicopathological characteristics and prognostic factors in combined hepatocellular carcinoma and cholangiocarcinoma.肝细胞癌合并胆管癌的临床病理特征及预后因素
Korean J Hepatobiliary Pancreat Surg. 2013 Nov;17(4):152-6. doi: 10.14701/kjhbps.2013.17.4.152. Epub 2013 Nov 20.
7
CD44 expression in patients with combined hepatocellular cholangiocarcinoma.肝内胆管癌合并肝细胞癌患者的CD44表达
Ann Surg Treat Res. 2015 Jul;89(1):9-16. doi: 10.4174/astr.2015.89.1.9. Epub 2015 Jun 11.
8
Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.通过整合微阵列分析对肝内胆管癌、肝细胞癌及肝细胞胆管癌联合样本的差异表达基因谱分析
Tumour Biol. 2015 Aug;36(8):5891-9. doi: 10.1007/s13277-015-3261-1. Epub 2015 Feb 26.
9
Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.具有胆管表型的肝癌的全基因组突变景观揭示了肝炎的影响和分子多样性。
Nat Commun. 2015 Jan 30;6:6120. doi: 10.1038/ncomms7120.
10
Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.肝细胞-胆管细胞癌合并症的危险因素:一项基于医院的病例对照研究。
World J Gastroenterol. 2014 Sep 21;20(35):12615-20. doi: 10.3748/wjg.v20.i35.12615.